Cargando…

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

[Image: see text] Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicycli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Chee Wei, Tan, Lendl, Sykes, Melissa L., AbuGharbiyeh, Neda, Debnath, Anjan, Reid, Janet C., West, Nicholas P., Avery, Vicky M., Cooper, Matthew A., Blaskovich, Mark A. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770830/
https://www.ncbi.nlm.nih.gov/pubmed/33151678
http://dx.doi.org/10.1021/acs.jmedchem.0c01372
_version_ 1783629592021434368
author Ang, Chee Wei
Tan, Lendl
Sykes, Melissa L.
AbuGharbiyeh, Neda
Debnath, Anjan
Reid, Janet C.
West, Nicholas P.
Avery, Vicky M.
Cooper, Matthew A.
Blaskovich, Mark A. T.
author_facet Ang, Chee Wei
Tan, Lendl
Sykes, Melissa L.
AbuGharbiyeh, Neda
Debnath, Anjan
Reid, Janet C.
West, Nicholas P.
Avery, Vicky M.
Cooper, Matthew A.
Blaskovich, Mark A. T.
author_sort Ang, Chee Wei
collection PubMed
description [Image: see text] Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure–activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.
format Online
Article
Text
id pubmed-7770830
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-77708302020-12-29 Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility Ang, Chee Wei Tan, Lendl Sykes, Melissa L. AbuGharbiyeh, Neda Debnath, Anjan Reid, Janet C. West, Nicholas P. Avery, Vicky M. Cooper, Matthew A. Blaskovich, Mark A. T. J Med Chem [Image: see text] Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure–activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization. American Chemical Society 2020-11-05 2020-12-24 /pmc/articles/PMC7770830/ /pubmed/33151678 http://dx.doi.org/10.1021/acs.jmedchem.0c01372 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Ang, Chee Wei
Tan, Lendl
Sykes, Melissa L.
AbuGharbiyeh, Neda
Debnath, Anjan
Reid, Janet C.
West, Nicholas P.
Avery, Vicky M.
Cooper, Matthew A.
Blaskovich, Mark A. T.
Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title_full Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title_fullStr Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title_full_unstemmed Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title_short Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
title_sort antitubercular and antiparasitic 2-nitroimidazopyrazinones with improved potency and solubility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770830/
https://www.ncbi.nlm.nih.gov/pubmed/33151678
http://dx.doi.org/10.1021/acs.jmedchem.0c01372
work_keys_str_mv AT angcheewei antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT tanlendl antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT sykesmelissal antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT abugharbiyehneda antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT debnathanjan antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT reidjanetc antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT westnicholasp antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT averyvickym antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT coopermatthewa antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility
AT blaskovichmarkat antitubercularandantiparasitic2nitroimidazopyrazinoneswithimprovedpotencyandsolubility